1. Clinical & Scientific Overview
Coenzyme Q10 (Ubiquinone / Ubiquinol) (TIP-MED-000633, Reference Code [SUP-09]) is classified under
Dietary Supplements & Nutraceuticals (FSSAI / ICMR-NIN) as a Clinical Nutrition & Nutraceutical Science • Lipophilic Mitochondrial Electron Transport Chain Carrier & Membrane Antioxidant.
Within the Indian regulatory and compendial framework, it is governed under FSSAI Nutraceutical Ingredient (Schedule IV / Nutraceutical List, typically 60–300 mg/day)..
FSSAI Licensed Health Supplement / Nutraceutical Formulations (RDA Compliant)
Typical Nutraceutical Supplemental Range: 100–200 mg/day taken with a fat-containing meal (softgel oil solubilised or Ubiquinol reduced form has 2–3x higher Cmax than dry crystalline powder capsules).
Clinical Nutrition, ICMR-NIN RDA & FSSAI Nutraceutical Profile
Coenzyme Q10 (Ubidecarenone)
Lipophilic Mitochondrial Electron Transport Chain Carrier & Membrane Antioxidant
Endogenous mevalonate pathway synthesis; dietary organ meats, sardines, peanuts, and soybean oil
ICMR-NIN 2024 Recommended Dietary Allowance (RDA) & Tolerable Upper Intake Limit (UL): Typical Nutraceutical Supplemental Range: 100–200 mg/day taken with a fat-containing meal (softgel oil solubilised or Ubiquinol reduced form has 2–3x higher Cmax than dry crystalline powder capsules).
Deficiency Clinical Syndromes vs Chronic Excess / Hypervitaminosis Risks: HMG-CoA reductase inhibitors (Statins: atorvastatin, rosuvastatin) block the mevalonate pathway upstream of farnesyl pyrophosphate, reducing endogenous serum CoQ10 levels by 25–40%; CoQ10 supplementation (100–200 mg/day) is widely used as a supportive adjunct in statin-associated muscle symptoms (SAMS) and studied in heart failure (Q-SYMBIO trial, always as an adjunct, never replacing GDMT).
Drug–Nutrient Chelation & Timing Interactions: CRITICAL WARFARIN INTERACTION: CoQ10 is structurally similar to Vitamin K2 (menaquinone) and can reduce the anticoagulant effect of Warfarin (decreasing INR and risking thrombosis) — monitor INR closely if starting or stopping CoQ10; mild insomnia if taken late at night.
FSSAI Health Supplement vs Therapeutic Drug Distinction: FSSAI Nutraceutical Ingredient (Schedule IV / Nutraceutical List, typically 60–300 mg/day).
3. Mechanism of Action & Pharmacodynamics
Mobile lipid-soluble electron carrier shuttling electrons from Complex I (NADH dehydrogenase) and Complex II (succinate dehydrogenase) to Complex III (cytochrome bc1 complex) in the inner mitochondrial membrane for oxidative phosphorylation ATP generation, while inhibiting lipid peroxidation in LDL particles.
4. Therapeutic Indications & Evidence-Supported Uses
- Physiological & Biochemical Role: Mobile lipid-soluble electron carrier shuttling electrons from Complex I (NADH dehydrogenase) and Complex II (succinate dehydrogenase) to Complex III (cytochrome bc1 complex) in the inner mitochondrial membrane for oxidative phosphorylation ATP generation, while inhibiting lipid peroxidation in LDL particles.
- Dietary Sources: Endogenous mevalonate pathway synthesis; dietary organ meats, sardines, peanuts, and soybean oil
- ICMR-NIN RDA & Upper Limits: Typical Nutraceutical Supplemental Range: 100–200 mg/day taken with a fat-containing meal (softgel oil solubilised or Ubiquinol reduced form has 2–3x higher Cmax than dry crystalline powder capsules).
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Typical Nutraceutical Supplemental Range: 100–200 mg/day taken with a fat-containing meal (softgel oil solubilised or Ubiquinol reduced form has 2–3x higher Cmax than dry crystalline powder capsules).
Administration & Meal Timing: CRITICAL WARFARIN INTERACTION: CoQ10 is structurally similar to Vitamin K2 (menaquinone) and can reduce the anticoagulant effect of Warfarin (decreasing INR and risking thrombosis) — monitor INR closely if starting or stopping CoQ10; mild insomnia if taken late at night.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Salt-form and meal-timing dependent gastrointestinal absorption; see bioavailability and drug-nutrient chelation notes (CRITICAL WARFARIN INTERACTION: CoQ10 is structurally similar to Vitamin K2 (menaquinone) and can reduce the anticoagulant effect of Warfarin (decreasing INR and risking thrombosis) — monitor INR closely if starting or stopping CoQ10; mild insomnia if taken late at night.).
Incorporated into cellular coenzyme pools, metalloproteins, or membrane phospholipids.
Caution with magnesium, potassium, calcium, vitamin D, and high-dose vitamin C/collagen (oxalate) in Chronic Kidney Disease.
Caution with fat-soluble vitamins and concentrated lipophilic extracts in hepatobiliary disease.
7. Contraindications, Precautions & High-Risk Warnings
- Supratherapeutic megadosing above the ICMR-NIN Tolerable Upper Intake Level (UL) without medical indication
- HMG-CoA reductase inhibitors (Statins: atorvastatin, rosuvastatin) block the mevalonate pathway upstream of farnesyl pyrophosphate, reducing endogenous serum CoQ10 levels by 25–40%; CoQ10 supplementation (100–200 mg/day) is widely used as a supportive adjunct in statin-associated muscle symptoms (SAMS) and studied in heart failure (Q-SYMBIO trial, always as an adjunct, never replacing GDMT).
Key Clinical Precautions: HMG-CoA reductase inhibitors (Statins: atorvastatin, rosuvastatin) block the mevalonate pathway upstream of farnesyl pyrophosphate, reducing endogenous serum CoQ10 levels by 25–40%; CoQ10 supplementation (100–200 mg/day) is widely used as a supportive adjunct in statin-associated muscle symptoms (SAMS) and studied in heart failure (Q-SYMBIO trial, always as an adjunct, never replacing GDMT).
8. Adverse Effects Profile
- HMG-CoA reductase inhibitors (Statins: atorvastatin, rosuvastatin) block the mevalonate pathway upstream of farnesyl pyrophosphate, reducing endogenous serum CoQ10 levels by 25–40%; CoQ10 supplementation (100–200 mg/day) is widely used as a supportive adjunct in statin-associated muscle symptoms (SAMS) and studied in heart failure (Q-SYMBIO trial, always as an adjunct, never replacing GDMT).
- HMG-CoA reductase inhibitors (Statins: atorvastatin, rosuvastatin) block the mevalonate pathway upstream of farnesyl pyrophosphate, reducing endogenous serum CoQ10 levels by 25–40%; CoQ10 supplementation (100–200 mg/day) is widely used as a supportive adjunct in statin-associated muscle symptoms (SAMS) and studied in heart failure (Q-SYMBIO trial, always as an adjunct, never replacing GDMT).
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- CRITICAL WARFARIN INTERACTION: CoQ10 is structurally similar to Vitamin K2 (menaquinone) and can reduce the anticoagulant effect of Warfarin (decreasing INR and risking thrombosis) — monitor INR closely if starting or stopping CoQ10; mild insomnia if taken late at night.
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Verify whether the patient requires physiological nutritional maintenance (<=1 RDA under FSSAI) or high-dose therapeutic deficiency correction (Schedule H/medical supervision), and check for multi-supplement stacking.
Pharmacist Patient Counselling Points:
- CRITICAL WARFARIN INTERACTION: CoQ10 is structurally similar to Vitamin K2 (menaquinone) and can reduce the anticoagulant effect of Warfarin (decreasing INR and risking thrombosis) — monitor INR closely if starting or stopping CoQ10; mild insomnia if taken late at night.
- Check all multivitamin and wellness labels to avoid accidentally doubling up on fat-soluble vitamins (A, D, E, K), iron, or zinc.
- Health supplements support normal physiological nutrition and are NOT intended to diagnose, treat, cure, or prevent disease under Section 22 of the FSS Act, 2006.
Storage, Stability & Dispensing Safeguards: Store in a cool, dry place below 25°C away from moisture and direct sunlight; verify FSSAI License Number and Veg/Non-Veg symbol on packaging.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: ICMR-NIN (National Institute of Nutrition) Nutrient Requirements and Recommended Dietary Allowances (RDA) for Indians (2020/2024); FSSAI (Health Supplements, Nutraceuticals, Food for Special Dietary Use, Food for Special Medical Purpose, Functional Food and Novel Food) Regulations, 2022.
Official Verification Portals: ICMR-National Institute of Nutrition (NIN) — Dietary Guidelines & Nutrient Requirements for Indians • FSSAI — Food Safety and Standards (Health Supplements and Nutraceuticals) Regulations
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.